Genentech to Invest $750M in Oregon Manufacturing Site

Genentech, a member of the Roche Group, plans to invest approximately $750 million into a new device fill-finish manufacturing facility at its 75-acre campus in Hillsboro, Oregon, bringing new end-to-end device filling capabilities to the site and expanding capacity to support the future pipeline of innovative medicines across Roche and Genentech.

The new facility will support the manufacturing of advanced drug delivery devices, such as pre-filled syringes and autoinjectors. Designed for flexibility, the facility will be capable of both high- and low-volume device filling across a broad range of Roche and Genentech’s portfolio, enabling the site to respond to changing manufacturing needs as the portfolio evolves.

The investment is expected to create 250 high-wage manufacturing jobs and approximately 200 construction jobs in Oregon during site development, with commercial operations expected to begin in 2031.

Genentech CEO Ashley Magargee said, “We are proud to make this significant new investment in Hillsboro, building on nearly two decades of Genentech manufacturing in Oregon. Thanks to its skilled workforce and strong community, Hillsboro remains vital to our U.S. operations. By adding end-to-end filling capabilities, this expansion deepens our commitment to manufacturing in the U.S. and gives us the flexibility to support a growing pipeline.”

The Hillsboro investment follows the recent topping out of Genentech’s new manufacturing facility in Holly Springs, North Carolina.